Treatment with adalimumab in amyloidosis secondary to rheumatoid arthritis: two case reports.
Rheumatological diseases and, firstly, rheumatoid arthritis (RA) remain a major cause of secondary amyloidosis. The emergence of biological agents such as adalimumab in the early treatment of RA can be an effective alternative to stop the development and progression of secondary amyloidosis. Not all patients will respond the same way to treatment; we must consider associated comorbidity, the poor prognosis factors for predicting therapeutic response and possible adverse effects. In the adverse effects of biological therapies, there has been an increase in the rate of lethal infections and congestive heart failure. We present two cases with renal amyloidosis secondary to RA who had a different clinical course: our 1st case had a good response to Adalimumab while the 2nd case evolved unfavourably after treatment, and died from cardiovascular complications.
Sección De Nefrología, Complejo Hospitalario La Mancha-Centro, Alcázar De San Juan, Ciudad Real, Spain. fikrioussamah@yahoo.fr
Oussamah
O
Fikri-Benbrahim
Francisco
F
Rivera-Hernández
Alberto
A
Martínez-Calero
Fátima
F
Cazalla-Cadenas
Rebeca
R
García-Agudo
Javier
J
Mancha-Ramos
D000068879:Adalimumab; D000368:Aged; D000686:Amyloidosis / Q000188:drug therapy* / Q000209:etiology*; D061067:Antibodies, Monoclonal, Humanized / Q000627:therapeutic use*; D018501:Antirheumatic Agents / Q000627:therapeutic use*; D001172:Arthritis, Rheumatoid / Q000150:complications*; D005260:Female; D006801:Humans; D007674:Kidney Diseases / Q000188:drug therapy* / Q000209:etiology*; D008875:Middle Aged
D061067:Antibodies, Monoclonal, Humanized; D018501:Antirheumatic Agents; D000068879:Adalimumab